明德生物(002932.SZ):擬向交通銀行太平洋支行申請短期流動資金貸款額度1.3億元
格隆匯7月20日丨明德生物(002932.SZ)公佈,公司於2021年7月20日召開第三屆董事會第十九次會議,審議通過了《關於向銀行申請綜合授信額度的議案》,根據公司生產經營和資金週轉需要,公司擬向交通銀行股份有限公司太平洋支行申請短期流動資金貸款額度人民幣1.3億元,授信期限為1年。公司將在1.3億元授信額度以內根據實際需求調劑使用,在不超過授信額度的情況下,無需再逐項提請公司董事會和股東大會審批。
以上授信額度不等於公司的實際融資金額,實際融資金額以銀行與公司實際發生的融資金額為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.